Sort   by:  
 Page size 
UnknownVariants in interferon-alpha pathway genes and response to pegylated interferon-Alpha2a plus ribavirin for treatment of chronic hepatitis C virus infection in the hepatitis C antiviral long-term treatment against cirrhosis trial.
Not available
S-EPMC2692559 | biostudies-literature
UnknownProlonged therapy of advanced chronic hepatitis C with low-dose peginterferon.
Not available
S-EPMC2606037 | biostudies-literature
UnknownOccult and previous hepatitis B virus infection are not associated with hepatocellular carcinoma in United States patients with chronic hepatitis C.
Not available
S-EPMC3134544 | biostudies-literature
UnknownCoffee intake is associated with lower rates of liver disease progression in chronic hepatitis C.
Not available
S-EPMC2783828 | biostudies-literature
UnknownIncidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease.
Not available
S-EPMC3749922 | biostudies-literature
UnknownPredicting cirrhosis and clinical outcomes in patients with advanced chronic hepatitis C with a panel of genetic markers (CRS7).
Not available
S-EPMC3215092 | biostudies-literature
UnknownCoffee consumption is associated with response to peginterferon and ribavirin therapy in patients with chronic hepatitis C.
Not available
S-EPMC3109110 | biostudies-literature
UnknownIron levels in hepatocytes and portal tract cells predict progression and outcomes of patients with advanced chronic hepatitis C.
Not available
S-EPMC3081953 | biostudies-literature
UnknownAn IL28B genotype-based clinical prediction model for treatment of chronic hepatitis C.
Not available
S-EPMC3132753 | biostudies-literature
UnknownA functional polymorphism in the epidermal growth factor gene is associated with risk for hepatocellular carcinoma.
Not available
S-EPMC3129453 | biostudies-literature
Sort   by:  
 Page size